Cite
Lin S, Green HD, Hendy P, et al. Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. J Crohns Colitis. 2020;14(12):1653-1661doi: 10.1093/ecco-jcc/jjaa104.
Lin, S., Green, H. D., Hendy, P., Heerasing, N. M., Chanchlani, N., Hamilton, B., Walker, G. J., Heap, G. A., Hobart, J., Martin, R. J., Coles, A. J., Silverberg, M. S., Irving, P. M., Chung-Faye, G., Silber, E., Cummings, J. R. F., Lytvyak, E., Andersen, V., Wood, A. R., Tyrrell, J., Beaumont, R. N., Weedon, M. N., Kennedy, N. A., Spiers, A., Harrower, T., Goodhand, J. R., & Ahmad, T. (2020). Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. Journal of Crohn's & colitis, 14(12), 1653-1661. https://doi.org/10.1093/ecco-jcc/jjaa104
Lin, Simeng, et al. "Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment." Journal of Crohn's & colitis vol. 14,12 (2020): 1653-1661. doi: https://doi.org/10.1093/ecco-jcc/jjaa104
Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, Coles AJ, Silverberg MS, Irving PM, Chung-Faye G, Silber E, Cummings JRF, Lytvyak E, Andersen V, Wood AR, Tyrrell J, Beaumont RN, Weedon MN, Kennedy NA, Spiers A, Harrower T, Goodhand JR, Ahmad T. Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. J Crohns Colitis. 2020 Dec 02;14(12):1653-1661. doi: 10.1093/ecco-jcc/jjaa104. PMID: 32497177.
Copy
Download .nbib